New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group.
Hiddemann
W
W
Department of Hematology and Oncology, University of Göttingen, Germany.
Unterhalt
M
M
Koch
P
P
Nahler
M
M
Herrmann
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005858:Germany; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000009:adverse effects; D011238:Prednimustine / Q000008:administration & dosage* / Q000009:adverse effects; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D016898:Interferon-alpha; D014750:Vincristine; D003520:Cyclophosphamide; D011238:Prednimustine; D008942:Mitoxantrone; D011241:Prednisone